This article is more than 5 years old. Information may no longer be current.
Hope on the Horizon for Celiac Disease
Click Here to Manage Email Alerts
From a time when celiac disease ranked low on the priority list for U.S. physicians, thought of as a European disease, recent developments point to a changing tide. Today, researchers across the globe pursue the next discovery in a disease on the rise and even American government agencies have joined the charge.
Healio Gastroenterology spoke to leading experts in the celiac field about the steps being taken and the discoveries being made.
“We now have the tools to show that patients can benefit symptomatically from a treatment, and we know what these trials look like,” Daniel Leffler, MD, MS, director of research for The Celiac Center at Beth Israel Deaconess Medical Center in Boston, told Healio Gastroenterology. “The FDA were really great partners in this, and have been really engaged in seeing celiac disease therapeutics move forward. We have made huge progress in the more than 5 years of patient-reported outcome development that have been done, which I think will stand the test of time and will be tools for the wider celiac community to use going forward.”
Leffler and other experts discussed the recent reversal of guidelines from the European Society for Pediatric Gastroenterology, Hepatology and Nutrition and what treatments are on the horizon.
Turn to the Drug/Device Pipeline in gastroenterology and let us know what you would like to see in the future. We continue to welcome your feedback on our peer-tested content, which is invaluable to us in our mission to deliver the most important and clinically relevant information to the gastroenterology community.
The Editors Healio Gastroenterology gastroenterology@slackinc.com